Aberdeen share price dips as tariff jitters hit London ahead of key update
19 January 2026
1 min read

Aberdeen share price dips as tariff jitters hit London ahead of key update

London, Jan 19, 2026, 14:35 GMT — Regular session

  • Shares of Aberdeen Group dropped roughly 2% in afternoon trading, shedding part of the gains they made last week
  • Broader UK equities dropped as renewed U.S. tariff threats shook risk appetite
  • Wednesday’s assets-and-flows update is drawing investor attention for signs of client money shifts

Shares in Aberdeen Group plc slipped 2.1% to 220.4 pence by 1435 GMT, marking it as one of the lagging financial stocks amid a risk-off mood in European markets. 1

The timing was crucial, coming as London markets wrestled with new trade tensions. The FTSE 100 fell 0.6% earlier following U.S. President Donald Trump’s threat to impose tariffs on Britain and seven other European countries, rattling investors and stirring worries of an escalating trade war. 2

Aberdeen investors face tricky timing. The firm will release its Q4 2025 assets under management (AUM) and flows update on Jan. 21, with full-year results set for March 3, as per its financial calendar. 3

“The market moves underline how disruptive tariff threats remain,” ING economists said. Capital.com analyst Kyle Rodda added that trade uncertainty might put “some downside pressure” on equities after a quiet start to the year. 4

Aberdeen’s shares continued their wild ride this month, moving between 217.8 pence and 224.0 pence on Monday, after kicking off the day at 221.0 pence, according to market data. 5

Aberdeen, previously known as abrdn, operates investment and adviser services. Its earnings often fluctuate with market conditions since fee income depends on assets under management. 6

Client money remains a major hurdle. In October, the firm posted another quarter of outflows and warned that more withdrawals were likely before year-end as it tried to turn around performance. 7

Management has shifted focus to sectors it considers more resilient. In December, Aberdeen announced plans to acquire roughly $2 billion in U.S. closed-end fund assets through a consolidation deal. 8

There’s a chance the tape turns choppy before any update arrives. Should the tariff threat become policy and volatility spike, asset managers face a double whammy — tumbling markets shrink fee-based assets, while jittery clients might start withdrawing funds.

The next key event is Wednesday’s AUM-and-flows update and analyst call. Investors will be watching closely for any indication that net flows are stabilising following recent market gains.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Centrica share price slips as Which? names British Gas among worst suppliers and tariff jitters hit London
Previous Story

Centrica share price slips as Which? names British Gas among worst suppliers and tariff jitters hit London

Apple stock price: AAPL braces for Tuesday’s reopen as tariff jitters hit tech, earnings near
Next Story

Apple stock price: AAPL braces for Tuesday’s reopen as tariff jitters hit tech, earnings near

Go toTop